These press releases are for business and financial media.
-
- 04 June 2009
- AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix AstraZeneca and Abbott announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott’s TRILIPIX, a medication for use alone or in combination with a statin to treat certain lipid disorders.
-
- 01 June 2009
- AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen AstraZeneca and Merck & Co., Inc. today announced a collaboration to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 from AstraZeneca.
-
- 29 May 2009
- AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult patients with major depressive disorder (MDD) to the Committee for Medicinal Products for Human Use (CHMP; a scientific committee of the European Medicines Agency, EMEA).
-
- 20 May 2009
- Court Grants AstraZeneca Preliminary Injunction Against Apotex in Pulmicort Respules Patent Litigation On 20 May 2009, the US District Court for the District of New Jersey granted AstraZeneca’s request for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.
-
- 11 May 2009
- AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA AstraZeneca today announced top line results from the phase III trial, PLATO, which demonstrate that BRILINTA, the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular (CV) events in patients with ACS.
-
- 30 April 2009
- AstraZeneca PLC First Quarter Results 2009 AstraZeneca has proved to be resilient in the first quarter of 2009, the result of excellent execution in driving growth in key product franchises and in all regions, whilst delivering improvements in operating efficiency.
-
- 23 April 2009
- IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval of the targeted oral anti-cancer drug, IRESSA (gefitinib).
-
- 23 April 2009
- US Food and Drug Administration Extends Review Timeline for Onglyza (Saxagliptin) New Drug Application AstraZeneca and Bristol-Myers Squibb reported today that the US Food and Drug Administration (FDA) has determined it needs additional time to complete the review of the New Drug Application (NDA) for ONGLYZA (saxagliptin) for the treatment of type 2 diabetes.
-
- 17 April 2009
- Court Grants AstraZeneca Temporary Restraining Order Against Apotex in Pulmicort Respules Patent Litigation On 16 April 2009, the US District Court for the District of New Jersey granted AstraZeneca’s request for a temporary restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca’s PULMICORT RESPULES until further order of the court.
-
- 09 April 2009
- FDA Advisory Committee Recommendation on Seroquel XR Supplemental New Drug Applications On 8 April 2009, the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee conducted a review of the safety and efficacy of supplemental new drug applications for SEROQUEL XR extended-release tablets proposed for the treatment of major depressive disorder and generalised anxiety disorder.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:09 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
